We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ERYTECH today announced its intention to move forward towards the submission of a BLA to the US Food and Drug Administration for eryaspase in hypersensitive acute lymphoblastic leukemia patients following feedback from the agency in a pre-BLA meeting.